Skip to main content

Advertisement

Table 3 The neutralizing antibody levels and protection against JEV infection in immunized mice

From: Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response

Treatment PRNT50a Survival rate (%)
Prime 1stboost 2ndboost
rMVA-mep 105TCID50 <5 <8 20±1.33 60c
106 TCID50 <7 9±1.33 33±2.33* 85c
107 TCID50 <8 18±2.33* 56±1.01** 100c
Inactivated JEV vaccine 9±1.33* 29±1.02** 58±2.01** 100c
EDIII 8±2.00* 28±1.99** 56±1.99** 100c
rMEP 9±1.01* 27±2.01** 57±1.99** 100c
Wild MVAb -- -- -- 0
PBSb -- -- -- 8.33
  1. a Prime-boost-boost vaccinations (days 0, 14 and 28) with rMVA-mep were carried out. On day 14 (prime), day 28 (first boost) and day 42 (second boost) sera were taken and analyzed. 50% plaque reduction neutralizing titer (PRNT50) was shown as the geometrical reciprocal of the sera dilution resulting in a 50% reduction.
  2. b No JEV-neutralizing antibodies were detectable in 1:2 diluted sera of the mice in the PBS and wild MVA groups. n = 12, values represent the mean ± standard error. Standard group is rMVA/M (105 TCID50).
  3. * Significance [p< 0.05 to animals immunized with rMVA/M (105TCID50)].
  4. **Significance [p<0.01 to animals immunized with rMVA/M (105TCID50)].
  5. c Significance (p< 0.05 to 8.33%).